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Recurrent pericarditis (RP) is a clinical syndrome characterized by recurrent attacks of
acute pericardial inflammation. Prognosis quoad vitam is good, although morbidity might
be significant, especially in children and adolescents. Multiple potential etiologies result in
RP, in the vast majority of cases through autoimmune or autoinflammatory mechanisms.
Idiopathic RP is one of the most frequent diagnoses, that requires the exclusion of
all known etiologies. Therapeutic advances in the last decade have been significant
with the recognition of the effectiveness of anti IL1 therapy, but a correct diagnostic
and therapeutic algorithm is of key importance. Unfortunately, most of evidence comes
from studies in adult patients. Here we review the etiopathogenesis, diagnosis and
management of RP in pediatric patients.
Keywords: pericarditis, myopericarditis, children, adolescents, pediatric, autoinflammatory diseases
PERICARDITIS: DEFINITIONS
Pericarditis is a clinical syndrome characterized by pericardial inflammation with or without
concurrent pericardial effusion.
According to the European Society of Cardiology (ESC) guidelines (1), diagnosis of acute
pericarditis requires at least two of the objective criteria listed in Table 1. The clinical course is
distinguished into acute, incessant, recurrent and chronic pericarditis by temporal cut-offs defined
by expert consensus (Table 1). Acute pericarditis accounts for 5% of the presentations to the
emergency department for chest pain in pediatric patients (3). After the attack has subsided, acute
pericarditis may recur leading to recurrent pericarditis (RP) in about 15–30% of adult patients (4, 5)
and in 35% of pediatric patients (6). Recurrences are frequently less severe than the first attack.
Most of evidence about pericarditis comes from studies on adults. However, RP in children and
adolescents is frequent, and has important specificities that will be review here.
ETIOLOGY, EPIDEMIOLOGY, AND DIAGNOSIS
Clinical and Etiological Classification
Acute pericarditis recognizes multiple etiologies, including infections, autoimmunity,
autoinflammation, genetic abnormalities, drugs, cardiac injuries, and undetermined causes
resulting in idiopathic pericarditis (Table 2). Most frequent etiologies show geographical variation
and depend on the clinical course. Worldwide, tuberculosis is the most common cause of
pericarditis. In developed countries, a viral infection is the most common cause of the first
pericarditis attack, while idiopathic RP (IRP) accounts for about 80% of adults and 70% of children
with RP.
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TABLE 1 | Definition and diagnostic criteria for pericarditis.
Definition and diagnostic criteria
Acute Pericarditis Acute (lasting <4–6 weeks) inflammatory pericardial
syndrome to be diagnosed by ≥2 of the following:
a) Pericardial chest pain* (prevalence in pediatric cases
90–95%)
b) Pericardial rubs (prevalence in pediatric cases 30%)
c) New widespread ST-elevation or PR depression on
ECG (prevalence in pediatric cases 40–50%)
d) Pericardial effusion (new or worsening,
prevalence in pediatric cases 70–80%)
Additional supporting findings:
- Elevated inflammatory markers (e.g., C-reactive protein,
erythrocyte sedimentation rate, and white blood cell
count)
- Pericardial inflammation at imaging (CT, CMR)
Recurrent pericarditis Recurrence of acute pericarditis after a documented first
episode and a symptom-free interval of ≥4–6 weeks
Adapted from Adler et al. (1) and Imazio et al. (2).
CT, computed tomography; ECG, electrocardiogram; CMR, cardiac magnetic resonance.
*Pericardial chest pain: typically sharp and with pleuritic features; improved by sitting and
leaning forward.
Idiopathic Recurrent Pericarditis (IRP)
Limited epidemiologic data are available for pediatric IRP. Acute
idiopathic pericarditis equally affects male and female children,
while being more prevalent in male among adolescents (9). The
reported incidence in the general population of acute pericarditis
is 30–150/105 per year (10, 11). Considering the probability of
recurrence and of alternative etiologies, the incidence of IRP
can be estimated at about 5–35/105 per year. After the first
recurrence, up to 50% of patients undergo further pericarditis
attacks (12, 13).
IRP is a diagnosis of exclusion, that can be made only
after an exhaustive screening. Invasive procedures (e.g.,
pericardiocentesis and pericardial biopsy) allow to increase the
sensitivity for specific etiologies (14), but are rarely performed
and there is no consensus about which tests should be performed
before concluding for IRP.
Despite that the term “idiopathic” reflects our ignorance about
the etiology of these conditions, recent advances have allowed an
increased awareness about the autoimmune/autoinflammatory
pathogenesis and about patients heterogeneity. In our experience,
there are three extreme phenotypes within IRP:
i) Recurrent attacks of pericarditis followed by complete
resolution with highly symptomatic serositis, high fever and
strikingly elevated acute-phase reactants. This phenotype
is particularly frequent in pediatric cases (2) and typically
shows a spectacular response to anti-interleukin-1 (IL1)
therapies such as anakinra (15). Important similarities
with autoinflammatory conditions (see below), suggests a
similar pathogenesis.
ii) Recurrent attacks with a subacute course, moderate
to high elevation of acute-phase reactants, frequent
autoantibody positivity (anti-nuclear antibodies, ANA,
anti-heart antibodies, AHA, and anti-intercalated disk
autoantibodies) and presence of other features occurring in
TABLE 2 | Most common etiologies of acute pericarditis in the pediatric age.
Infectious# Purulent – pyogenic bacteria
Tubercular
Viral* (adenovirus, enterovirus, parvovirus, influenza A,
cytomegalovirus, Epstein-Barr Virus, human
herpesvirus-6)
Other: Lyme’s disease, Histoplasma capsulatum, and
opportunistic infections in immunocompromised patients
Autoimmune Connective tissue diseases* (systemic lupus
erythematous [SLE], dermatomyositis)
Arthritis (Systemic-onset juvenile idiopathic arthritis
[so-JIA]*, rheumatic fever*)
Vasculitis* (Takayasu, Kawasaki, Behçet disease and
ANCA-associated vasculitides)
Sarcoidosis*
Inflammatory bowel diseases*
Autoinflammatory Familiar Mediterranean Fever (FMF)*
TNF receptor-associated periodic syndrome (TRAPS)*
Other genetic
conditions
Camptodactyly–arthropathy–coxa vara–
pericarditis (CACP) syndrome
Iatrogenic Chemotherapy- and radiotherapy- related
Immune checkpoint-inhibitors (7)
Drug-related SLE (8)
Hypersensitivity (e.g., penicillins, mesalamine,
sulfasalazine, infliximab)
Post-cardiac
injury
Myocardial infarction, pericardiotomy*, pericardial
bleeding*, percutaneous coronary intervention*,
pacemaker lead insertion*, radiofrequency ablation*,
chest trauma*
Miscellaneous Malignancies
Uremia
Mixedema
Anorexia nervosa
Idiopathic *
*Potential evolution to recurrent pericarditis.
#Potentially favored by inherited or acquired immune deficiencies.
systemic autoimmune diseases (e.g., arthralgias, xeroftalmia,
Raynaud’s phenomenon, discoid lupus, uveitis). Autoimmune
mechanisms are believed to play an important role in these
patients. However, we highlight that autoantibodies are not a
specific markers of an autoimmune pathogenesis, as they may
be an epiphenomenon of pericardial inflammation.
iii) Patients with mild attacks with a subacute or grumbling
course, smoldering elevation of inflammatorymarkers, and no
evidence of autoimmunity.
Post-cardiac Injury Recurrent Pericarditis
Post-cardiac injury syndromes are characterized by pleuro-
pericarditis occurring after myocardial infarction, chest trauma,
cardiac surgery, and percutaneous procedures including
angioplasty/coronary stenting, cardiovascular implantable
electronic device lead insertion and radiofrequency ablation
(16–18). Among these, post-pericardiotomy (PP) pericarditis
is the best-characterized condition. PP pericarditis occurs after
heart surgery in about 15–30% of subjects (19, 20), typically
within 3 months. The observed risk to develop RP after the first
attack ranges between 1 and 2% in the studies performed in the
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last decade (19, 20) and 50% in those performed in the early 90s’
(50%) (21).
It is debated whether pediatric patients have a higher risk
than adults to develop PP-pericarditis and PP-RP. Observational
studies on pediatric cohorts of RP have reported that PP cases
account for about 10% of children and adolescents with PR
(2). The risk of development of PP-pericarditis in children
undergoing heart surgerymight be particularly high after surgical
repair of atrial septal defects (22); being reported to range
between 10 and 28% (23–25), which is similar to what observed
in adults.
Secondary RP
RP in Systemic Autoimmune Disorders
Pericarditis is a frequent finding in patients with systemic
autoimmune disorders (Table 2). In general, pericarditis in
the setting of systemic autoimmunity might follow ether a
chronic or an acute/subacute course reflecting the inflammatory
activity of the underlying disease with multiple potential
recurrences. On average, pericardial effusion tends to be larger
but less symptomatic than that observed in idiopathic or viral
pericarditis (26).
In the setting of systemic autoimmunity, the diagnostic work-
up should screen for involvement of other heart structures, and
consider specific complications related to immunosuppression
such as lymphoproliferative diseases or infections.
Systemic lupus erythematosus (SLE) and connective-tissue
diseases
SLE is the prototypic connective tissue disease, mainly affecting
young women with a chronic-relapsing course. Up to 20% of SLE
patients experience disease onset during infancy of adolescence
(27). Heterogeneity in terms of disease severity and pattern of
involvement is substantial, as SLE can involve most body tissues
and organs. Prevalence of symptomatic pericarditis is about 25%
in adults (28), and appears to be even higher in childhood-onset
SLE (29). Although pericardial involvement is the most common
cause of symptomatic heart disease in SLE, it is frequently
asymptomatic and seldom results in major complications such as
cardiac tamponade or pericardial constriction (26, 30, 31).
Idiopathic inflammatory myopathies, in particular
dermatomyositis, are another connective tissue diseases
that may affects pediatric patients (32–34). Although the skin
and striated muscles are typical disease targets, pericardial
involvement and pericarditis have been described, with lower
frequency than SLE (26).
Systemic-onset juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) represent a heterogeneous
group of diseases that globally accounts for most of childhood
chronic rheumatic conditions (35). Systemic-onset JIA (SoJIA,
also known as Still’s disease) is characterized by polyarthritis,
high-spiking fever with prominent acute-phase response,
a fleeting pink skin rash, generalized lymphadenopathy,
hepatosplenomegaly, and sometimes serositis. SoJIA
pathogenesis include dysregulation in innate and adaptive
immunity, thus presenting features of both autoimmune
and autoinflammatory conditions. Cardiac involvement,
predominantly pericarditis, is estimated to occur clinically in
10% of cases, and echocardiographic signs are observed in
more than 30% of the cases (36, 37). Pericardial tamponade
is uncommon, especially after therapy has been undertaken
(38). Children and adolescents suffering from other forms of
JIA might have asymptomatic pericardial effusion or a typically
mild and benign pericarditis in up to 30 and 10% of cases,
respectively (39).
Rheumatic fever (RF)
RF is a relapsing autoimmune disorder triggered by group-
A streptococci infection in predisposed subjects. Inflammation
typically affects the joints and the heart, and sometimes also
the skin and the brain basal ganglia (40). Pathogenesis is due
to molecular mimicry between streptococcal M protein and
self-antigens. Pericarditis during RF is a sign of rheumatic
carditis. Usually, it occurs at the initial episode, within
1 week after appearance of fever and arthritis (26), but
sometimes is the presenting manifestation of RF or can
present during relapses of RF (41). Pericarditis usually resolves
without sequelae and does not require a specific management
in addition to that for rheumatic carditis (antibiotics to
eradicate streptococcal infection, salicilates, glucocorticoids, and
management of valvulopathy and heart failure) (40).
Vasculitis
Pediatric vasculitides might uncommonly result in pericarditis.
Despite being the most common pediatric vasculitis, Henoch-
Schonlein purpura is not associated with pericarditis, as
coexistence of the two has been reported only once (42).
Kawasaki disease is an acute, self-limiting muco-cutaneous
febrile illness typically affecting children and characterized by
small- and medium-sized arteries and frequently resulting in
remodeling of coronary artery with stenosis or aneurysm.
Pericardial effusion is frequently observed and is predictive of
coronaritis and coronary artery remodeling (43). However, overt
pericarditis is uncommon and typically uniphasic (44).
Takayasu arteritis is the prototypic large-vessel vasculitis (45,
46), and is the third most frequent pediatric vasculitis (47).
Takayasu arteritis might be associated with pericarditis at disease
onset or in the case of very high disease activity (48).
Behçet’s disease can affect arteries and veins of variable size,
skin and oral/genital mucosa, the bowel, the eye and the CNS
(49). Five to ten percent of patients experience disease onset
during childhood (50). Despite that Behçet’s disease seldom
affects the heart, pericarditis is the most common type of heart
involvement (51).
ANCA-associated vasculitides (AAVs) are small-vessel
vasculitides that can rarely affect pediatric patients. Although
infrequently, pericarditis may be associated with active
AAVs (26, 52).
Sarcoidosis
Sarcoidosis is the prototypic idiopathic granulomatous disease
and affects multiple organs, mainly the lymph nodes and the
lungs (53). Disease onset during childhood or adolescence
Frontiers in Pediatrics | www.frontiersin.org 3 October 2019 | Volume 7 | Article 419
Tombetti et al. Recurrent Pericarditis in Pediatric Patients
occurs in <10% of subjects. Heart involvement might lead to
cardiomyopathy with heart failure, conduction abnormalities,
and arrhythmias. Mild to moderate pericardial effusion is
frequently present during active sarcoidosis, while pericarditis is
rare but can occur with a relapsing course (26).
Inflammatory bowel diseases
Inflammatory bowel diseases (IBDs) are chronic-relapsing
inflammatory conditions, mainly represented by Crohn’s disease
and ulcerative colitis, that primarily affect the gut. Pediatric
onset occurs in about 15–20% of subjects and portend a poorer
prognosis (54). Extra-intestinal inflammatory involvement
occurs in about a third of patients. Pericarditis is the most
frequent extra-intestinal manifestation of IBDs, being reported
in about 70% of subjects with cardiovascular complications (55).
Pericarditis in the setting of IBD might follow a relapsing course
and sometimes has onset before intestinal manifestations (56).
Concurrent myocardial involvement is not rare and frequently
depends on hypersensitivity to aminosalicylate therapy with
mesalamine or sulfasalazine (55, 57–59).
RP in Autoinflammatory Disorders
Autoinflammatory diseases are a recently-recognized
group of disorders in which inflammation results from
dysregulated innate immunity rather than from autoimmunity.
Many autoinflammatory diseases have been recognized as
genetic disorders caused by mutations in key regulators of
innate immunity. Although not being part of the typical
disease features, pericarditis has been described in the
setting of multiple autoinflammatory conditions, including
Hyperimmunoglobulinemia D with periodic fever syndrome
(HIDS) (60), NOD2-associated autoinflammatory syndrome
(61), and chronic atypical neutrophilic dermatosis with
lipodystrophy and elevated temperature (CANDLE) (62). On
the contrary, two autoinflammatory conditions, namely Familial
Mediterranean Fever (FMF) and TNF receptor-associated
periodic syndrome (TRAPS), are closely related to IRP because
of clinical similarities and a similar response to colchicine and
anti-IL1 therapies such as anakinra.
Familiar Mediterranean Fever (FMF)
FMF is the most common monogenic autoinflammatory disease.
It characterized by episodes lasting 1–3 days with fever, systemic
inflammation, serositis and oligoarthritis (63). Overt peritonitis
occurs in more than 90% of cases, pleuritis in about 40%,
and pericarditis in about 5% (64–66). Subclinical pericardial
disease might be more prevalent, as echocardiographic signs of
pericardial effusion or thickening are present in up to 27% of
patients (67). Pericarditis attacks during FMF often have a benign
course without sequelae and tend to occur later in life (68).
TRAPS
TRAPS is a genetic condition characterized by febrile attacks
lasting several days to weeks, associated with migratory erythema
with underlying myalgia, ocular inflammation, arthralgia and/or
arthritis, and serositis (69). Clinical and genetic heterogeneity
of TRAPS is substantial, and attacks with isolated pericarditis
have been described. Indeed, TRAPS mutations sometimes
TABLE 3 | Prognostic factors predictive of complication or recurrence (1).
Major Fever > 38◦C
Subacute onset
Large pericardial effusion (>20mm)
Cardiac tamponade
Lack of response to Aspirin or NSAID after ≥1 week
of treatment
Minor Myocardial involvement
Immunosuppression
Trauma
Anticoagulant therapy
are identified in subjects with colchicine-refractory or steroid-
dependent RP (70).
RP Secondary to Other Pediatric Disorders
Camptodactyly–Arthropathy–Coxa Vara–Pericarditis
(CACP) Syndrome
CACP syndrome is characterized by symmetrical, non-
inflammatory arthropathy, synovial hyperplasia, congenital
or early-onset camptodactyly, progressive coxa vara, and
pericarditis. It is caused by mutations in the proteoglycan 4 gene,
which encodes lubricin, a lubricating glycoprotein of synovial
fluid, articular cartilage and pericardium. Lubricin absence
results in pericardial adhesions and fibrosis (71).
Non-inflammatory pericardial effusion is reported in up to
30% cases of CACP syndrome. Ascites and pleural effusions
are uncommon. Pericarditis has a variable course, from a
self-limiting condition to a chronic and constrictive evolution
requiring surgical intervention.
Diagnostic Specificities in the Pediatric
Age
The ESC guidelines highlight that search for etiology is not
mandatory at the first pericarditis attack in the absence of factors
for a poor prognosis (Table 3) or of features suggestive of specific
causes (1). However, RP represents a different scenario especially
in children, where specific etiologies occur most frequently than
in adults. In pediatric patients, high attention should be paid to
identify genetic causes that might entail a specific management.
Red flags for considering genetic screening for FMF or TRAPS
are: (i) familiarity for RP or autoinflammatory diseases, (ii) a
personal history of periodic fever, or (iii) colchicine-refractory or
steroid-dependent RP.
PATHOGENESIS
IRP results from an interplay between environmental triggers,
genetic predisposition and the immune system. The triggers
of recurrence remain to be clarified. Recurrences are not
associated with clinical features suggestive of a concurrent
viral infection: it has been proposed that a tolerance break
toward pericardial antigens at the first attack may pave the way
for subsequent relapses. According to this view, dysregulated
adaptive immunity and autoimmunity have a central role
in IRP pathogenesis. This paradigm is supported by several
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observations, such as: (a) the occurrence of pericarditis in
autoimmune diseases (72, 73), (b) the association of IRP with
cardiac-specific and non-cardiac specific autoantibodies, such as
antinuclear antibodies (ANA), anti-heart antibodies (AHA) and
anti-intercalated disk antibodies (AIDA) (74), (c) the efficacy
of steroids, of immunosuppressive agents targeting cellular
immunity (e.g., azathioprine) and of immune-modulatory drugs
such as intravenous immunoglobulin (75–79), and (d) the
association of IRP with specific alleles in the human leukocyte
antigen (HLA)–A, -C, and -DQB1 (80). Recently, this traditional
view of IRP as an autoimmune disorder has been challenged
by the discovery that dysregulated innate immunity is the
driver of a group of inflammatory conditions, thus named
“autoinflammatory diseases.”
Innate immunity is triggered by germ-line encoded receptors
expressed by multiple cell lines and results in an inflammatory
response. These receptors recognize signals derived from
microbial constituents (PAMPs, pathogen-associated molecular
patterns) or from damaged tissue components (DAMPs, damage-
associated molecular patterns). A crucial step in modulation
of inflammation is the regulation of inflammasome activity
(81). Inflammasomes are a family of multimeric complexes that
activate caspase-1 and other proteases involved in inflammation.
Inflammasomes are activated by specific sensor proteins
belonging to the nucleotide-binding oligomerisation domain-
like receptor (NLR) family. Upon stimulation, sensor proteins
self-assemble into complexes (the inflammasomes) that recruit
pro-caspase 1 (81). The adaptor protein ASC (Apoptosis Speck-
like protein with a CARD domain) facilitates assembly and
is typically required for efficient caspase 1 activation. One of
the best-characterized inflammasomes derives from the sensor
protein NLRP3 (NLR pyrine domain-containing-3). Recognition
of multiple viral PAMPs and several DAMPs, such as urate
crystals in gout and cholesterol in atherosclerosis (82–84),
results in NLRP3 inflammasome activation and IL1 production
(Figure 1). Gain-of-function mutations in the gene encoding
pyrine, another sensor protein, may cause hyperactivity of pyrin
inflammasome and result in FMF. A different inflammatory
mechanism underlies TRAPS, which is caused by gain-of-
function mutations in the receptor for Tumor Necrosis Factor
(TNF)-α (69). Relatives of patients with TRAPS are frequently
diagnosed with IPR, suggesting an overlap these conditions,
especially for patients with low-penetrance mutations that may
have a delayed disease onset or an incomplete TRAPS phenotype
(85, 86).
The recognition that sterile pericarditis may derive from either
dysregulated adaptive or innate immunity led to the proposal
of an autoimmune and an autoinflammatory phenotype of IRP
(87). However, distinction between the two is not is not always
straightforward, due to the absence of specific biomarkers and to
the strong overlap between innate and adaptive immunity, which
are intrinsically co-entangled.
Similarly, the pathogenesis of post-cardiac injury pericarditis
is poorly understood (16, 17). An autoimmune mechanism has
been proposed to explain the onset of relapsing inflammation
after tissue damage. Indeed, cardiac injury may result in
the presentation of cardiac antigens in an immunogenic
context. However, post-cardiac injury pericarditis has been
observed in severely immunocompromised children after heart
transplantation (88), suggesting that mechanisms alternative to
autoimmunity can sustain inflammation. It logical to speculate
that strong pathogenic similarities exist between IRP and post-
cardiac injury RP, both resulting from dysregulated innate and/or
adaptive immunity.
PROGNOSIS OF RECURRENT
PERICARDITIS IN THE PEDIATRIC AGE
Prognosis of IRP is good in terms of mortality. No deaths
were observed in children hospitalized for acute idiopathic
or viral pericarditis in the pediatric health information
system (PHIS) database (9). However, morbidity is significant
due to multiple recurrences, medication side effects, or
occurrence of complications such as cardiac tamponade,
pericardial constriction and myocardial involvement. Prognostic
factors associated with an increased risk of recurrences or of
complications have been identified (Table 3), although they have
been derived from unselected cohorts of patients with pericarditis
and never validated in pediatric cohorts.
Cardiac tamponade typically occurs upon rapid accumulation
of fluid in the pericardium, such as in the case of neoplastic
pericarditis. Cardiac tamponade is much rarer (about 1–2%
of cases) in idiopathic or in viral acute pericarditis (89).
Cardiac tamponade complicates the first pericarditis attack more
frequently than recurrences (90). Prevalence of tamponade in
post-cardiac injury pericarditis is higher, being reported in 5–
20% of subjects (19, 91, 92). Cardiac tamponade warrants prompt
pericardiocentesis, but subsequent clinical course is similar to
uncomplicated pericarditis (75).
Pericardial constriction is a hemodynamic condition due to
hampering of diastolic filling of ventricles by a fibrotic and
inextensible pericardium. Occurrence of pericardial constriction
is rare (1–2% at 6 years of follow-up) in patients with idiopathic
or viral pericarditis, relatively infrequent (2–13%) in those with
post-cardiac injury pericarditis or pericarditis in the settings of
other systemic autoimmune disorders, and frequent (20–30%)
in the case of tubercular, purulent or post-actinic pericarditis
(91, 93). Pericardial constriction has never been reported in IRP
(90, 94). Severe constriction requires surgical pericardiectomy,
although medical therapy with NSAIDs sometimes results in
improvement in the case of viral, idiopathic or immune-mediated
pericarditis (95, 96).
Myocardial involvement during acute pericarditis occurs in
about 15% of adult subjects (75) and up to 35% of pediatric
patients (97). Myocardial inflammation is revealed by increased
troponin levels or by myocardial inflammation/fibrosis at
cardiac magnetic resonance (MR). It has been proposed to
distinguish two conditions with concomitant pericardial and
myocardial inflammation: myopericarditis and perimyocarditis.
The former is characterized by predominant pericardial
inflammation extending from the epicardial fat to the
myocardium. Myopericarditis has clinical features highly
similar to pericarditis and usually follow a benign course with a
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FIGURE 1 | Drivers of pericardial inflammation. Autoimmunity against cardiac antigens as well as dysregulated innate immunity might result in pericardial inflammation.
Innate immunity is activated by receptors for pathogen- or damage-associated molecular patterns (PAMPs and DAMPs, respectively). Crucial innate immunity
pathways leading to pericardial inflammation depend on inflammasome activity and on TNF receptor-1 (TNFR1). The inflammasome is a multimolecular complex
composed of sensor protein such as NLRP3 or pyrin (that self-assemble upon activation), stimuli such as NLRP3 or pyrin, adaptor proteins such as ASC, and
pro-caspase-1. Upon inflammasome assembly, pro-caspase 1 releases active caspase 1, which can process pro-IL1 to active IL1. AHA: anti-heart antibodies, AIDA:
anti-intercalated disc antibodies.
reduced risk of recurrences or cardiac tamponade. Conversely,
perimyocarditis patients tend to have less intense pericardial
pain and elevation of acute-phase reactants but prominent
myocardial inflammation with regional or global reduction in
systolic function (98). Most of these patients recover a normal
left ventricular function after the resolution of the attack.
ROLE OF IMAGING
In patients with cardio-respiratory symptoms, chest X-ray
may reveal concomitant conditions or alternative diagnosis to
pericarditis, or identify pleural and pericardial effusion. Thus,
chest X-ray is the first imaging technique usually performed,
although it is inaccurate in the quantification of the amount of
pericardial fluid, and it is unable to assess the cardiac function
and to differentiate among the various etiologies of pericarditis.
Echocardiography is the technique of choice, it is widely
and rapidly available, and can be repeated during follow-up.
It allows to study the dimensions and functions of cardiac
chambers and valves. Signs suggestive of active pericarditis are
pericardial effusion and hyperechoic pericardium. In addition,
echocardiography may quantify pericardial effusion and reveal
potential complications such as cardiac tamponade, systolic
dysfunction as well as signs of pericardial constriction.
In selected cases, cardiac MR might be complementary to
echocardiography, thanks to its ability to (i) provide an excellent
depiction of cardiac and pericardial morphology together with
a good quantification of pericardial effusion and ventricular or
valvular function, (ii) characterize myocardial and pericardial
tissue in terms of inflammation, edema and fibrosis, and (iii)
reveal findings suggestive for concomitant diseases, such in the
case of autoimmune diseases, large-vessels vasculitis, thoracic
lymphadenopathies, or cardiac tumors. Acquisition protocols
specific for pediatric patients may require to take into account
small heart dimension and fast heart rates and to ensure reliable
breath-holding (99). Briefly, specific signs of active pericardial
inflammation at MR are pericardial edema (hyperintensity on
T2-weighted short-tau inverted recovery [STIR] sequences)
and pericardial late gadolinium enhancement (LGE, meaning
pericardial signal enhancement in T1-weighted sequences
obtained 10min after contrast medium administration).
Pericardial thickening (>4mm) is not considered a specific
sign of active pericarditis because it can be observed in
multiple pericardial disorders including pericardial constriction
or neoplasms. Cardiac MR might also revel concomitant
myocarditis. It is proposed that the kinetic of gadolinium
ingress and egress differs between the pericardium and the
myocardium. Accordingly, active myocardial inflammation
is heralded by edema and early gadolinium enhancement
(observed on T1-weighted sequences obtained after about 2min
after contrast medium administration). Differently from the
pericardium, myocardial late gadolinium-enhancement reveals
fibrosis (75).
Given the specificities of cardiac MR, its indications in
the setting of pericarditis are: (i) atypical cases, to confirm
pericarditis or identify alternative diagnoses, (ii) pericardial
constriction or myocardial involvement, and (iii) RP associated
to specific etiologies such as large-vessel vasculitis (100), and (iv)
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TABLE 4 | Medical therapy for recurrent pericarditis in children.
Agent Starting dose
NSAID
Ibuprofen 30–50 mg/kg daily, divided every 6–8 h
Indomethacin 2 mg/kg daily, divided every 6–12 h
Colchicine 0.5 mg/day before 5 years of age
1–1.5 mg/day after 5 year of age
Anakinra 1–2 mg/kg daily up to 100mg daily subcutaneously
Start tapering not before 3–6 months of remission
Prednisone 0.5–2 mg/kg daily
IVIG 400–500 mg/kg for 5 days (repeatable once a month)
need to tailor therapy according to the intensity or persistence of
pericardial inflammation (101).
Computed tomography (CT) is another complementary
technique. Similarly to MR, CT provides good anatomic images
and may quantify pericardial thickness, the volume of pericardial
effusion or the presence of localized effusion. In addition,
CT can assess the presence of pericardial calcifications and
define the attenuation values of the pericardial fluid which
might be of help in the diagnostic workup: high values suggest
hemorrhage, intermediate values exudative effusions and low
values trasudative effusions (102). CT is particularly useful in the
initial diagnostic work-up to exclude specific etiologies including
malignancies and tuberculosis, and in the preoperative planning
of pericardiectomy.
MANAGEMENT OF RECURRENT
PERICARDITIS IN THE PEDIATRIC AGE
Management of pediatric patients with RP is derived from
the experience with adult patients: it includes medical and
interventional therapies, and lifestyle recommendations.
After correct diagnostic workflow, therapy should be targeted
to the underlying etiopathogenesis as much as possible,
aiming at inducing remission and preventing recurrences and
complications. Primary prevention of pericarditis (e.g., in the
setting of cardiac surgery) is beyond the scope of this review.
Available evidence has not suggested important differences in the
management of recurrences and remission phases of post-cardiac
injury RP and IRP.
Management of Acute Attacks
Admission should be considered in presence of severe pain or
predictors of poor prognosis (Table 3) (1). Acute pericarditis
should be treated with high-dose NSAIDs in combination with
colchicine, except for specific etiologies requiring alternative
treatments or for refractory subjects (1). High-dose aspirin is
generally not used in pediatric patients, due to concerns about the
risk of Reye syndrome. In this setting, ibuprofen (30–50 mg/kg
daily, divided every 6–8 h) or indomethacin (2 mg/kg daily,
divided every 6–12 h, Table 4) are valid options. Intravenous
administration might be useful to achieve rapid pain control in
hospitalized patients.
Colchicine is an anti-gout medication that is also active
for FMF (103) and pericarditis. Colchicine concentrates
within leukocytes (especially granulocytes) and inhibits
microtubule assembly, thus limiting cell motility, phagocytosis,
and degranulation. Moreover, colchicine downregulates NLRP3
inflammasome by antagonizing caspase-1 activity and potential
triggering factors (e.g., P2X2 and P2X7 channels and Reactive
Oxygen Species) (104). Gastrointestinal intolerance is the most
common side effect, it is dose-dependent and reported in about
5–10% of adults (5, 12, 13), although children might tolerate
higher per kilo doses than adults. Studies have shown that
colchicine hastens the response to treatment and decreases the
risk of recurrences of about 50% (105). Moreover, colchicine
reduces the risk of pericardial constriction in PP pericarditis
(91). Unfortunately, little evidence is available about colchicine
in pediatric patients with RP (106): a recent observational
study reported a 65% reduction of recurrences (2). Moreover,
colchicine therapy in pregnant women with IRP raised no
concerns about fetal toxicity (107). Despite this encouraging data
about safety and efficacy in children with RP, colchicine remains
underprescribed in the pediatric population (9, 108).
Currently, steroids are used as second line therapy in adults
with sever acute pericarditis or with colchicine-refractory RP:
they are rapidly effective but they favor recurrences and steroid-
dependence, especially if used at high doses (109, 110). In
children, steroids may cause growth retardation, acne, striae
rubrae, and predisposition to osteoporosis. Therefore, steroids
should be avoided as much as possible in pediatric IRP by
means of the following recommendations: (i) to use NSAIDs at
the maximum tolerated does or (ii) to intravenously administer
NSAIDs in hospitalized patients, and (iii) to consider the use
of anti-IL1 therapy after failure of high dose NSAIDs combined
with colchicine. Alternatively, steroids should be started at the
lowest effective dose, and slowly tapered after remission has
been obtained.
Anti-IL1 therapy with anakinra (1–2 mg/kg daily
subcutaneously) is the most important advance in the last
decade for the field (111). Anakinra is efficacious for multiple
autoinflammatory diseases including FMF. Thus, it has been
initially used in children with refractory IRP. Subsequent
experience including a clinical trial has shown that anakinra has
spectacular effects in refractory or steroid-dependent IRP with
raised acute-phase reactants (2, 15, 112–114). Children with IRP
frequently have an “autoinflammatory phenotype” (2) that is
particularly responsive to anakinra. Anakinra has a very good
safety profile, due to its short half-life and low risk of infections
and of reactivation of tuberculosis. Severe reactions are rare,
but injections site-reactions are frequent in the first month of
treatment, and then disappear (111). Thus, anakinra should be
considered as a second line agent for children and adolescents
with IRP with raised acute-phase reactants that is refractory to
NSAIDs and colchicine.
Intravenous immunoglobulins (IVIG) are used for refractory
cases at the dose of is 400–500 mg/kg for 5 days, potentially
repeatable after 1 month (2, 77–79). A systematic review about
IVIG for RP including 19 adults and 11 pediatric patients, showed
good efficacy and safety of IVIG (79). The main limitations
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TABLE 5 | Tapering of glucocorticoids in children.
Daily dose* Tapering
>0.7 mg/kg 0.14 mg/kg*day every 1–2 weeks
0.35–0.7 mg/kg 0.7–14 mg/kg*day every 1–2 weeks
0.2–35 mg/kg 0.035 mg/kg*day every 2–4 weeks
< 0.2 mg/kg 0.017–0.035 mg/day every 2–6 weeks
*Doses are expressed as prednisone-equivalents.
of IVIG are costs, the intravenous administration and the
administration schedule. Since anti-IL1 therapy has become
available for IRP, the role of IVIG is mainly limited to patients
with autoimmune features.
RP in the setting of specific etiologies should be treated
accordingly to the underlying disease. Specifically, RP in
the setting of FMF should be treated with colchicine and
anti-IL1 therapies (anakinra, rilonacept, canakinumab) for
refractory cases (63). In RP due to TRAPS patients should
be treated with NSAIDs, steroids and anti-IL1 treatments or
etanercept (115, 116). SLE-associated RP should be treated
with a combination of hydroxychloroquine, a brief steroid
course and immunosuppressive agents such as azathioprine and
mycophenolate mofetil (117, 118).
Prevention of Recurrences and Other
Complications
After complete remission (absence of symptoms and of raised
acute-phase reactants) has been achieved, therapy can be slowly
tapered, reducing a single class of drug at a time. Steroids
and high-dose NSAIDs are tapered first. Table 5 shows the
steroid-tapering schedule that we follow in pediatric patients
with IRP, directly derived from recommendations for adult
patients (1). Recurrences are particularly frequent when steroids
are tapered below 0.2 mg/kg∗day of prednisone-equivalent, and
small decrements are advisable every at least 2–6 weeks (e.g.,
reductions of 1–2.5mg on alternate days). Tapering of anakinra
should not start before 3–6 months of sustained remission, and
should be performed very slowly due to high risk of recurrences.
Slow-acting medications including hydroxicloroquine or
immunosuppressive agents such as azathioprine, mycophenolate
or cyclosporine (2, 76), have been proposed as 3rd or
4th line medications to prevent recurrences in the cases
of refractoriness to anakinra or of features suggestive of
autoimmune pathogenesis.
With the exception of acute-phase reactants, we lack
biomarkers to guide therapeutic tapering during remission and
to predict future exacerbations. Cardiac MR has been proposed
at this purpose, although its use in young children might be
troublesome because of durations of acquisition and capability
to ensure adequate breath holds.
Interventional Therapy for Relapsing
Pericarditis
Cardiac tamponade requires emergent pericardiocentesis
to restore adequate heart filling. Selected cases of acute
pericarditis (mainly at the first episode) might require diagnostic
pericardiocentesis if specific etiologies are suspected, including
neoplasms or bacteria.
Surgical pleuropericardial window is another options that
might be considered for subjects at risk of recurrent pericardial
tamponade. In the case of severe or chronic pericardial
constriction or of RP refractory to multiple therapeutic lines,
surgical pericardiectomy might be of help. However, evidence
about pericardiectomy for refractory RP is limited to adults (119),
and this procedures should be considered only as an extrema ratio
in pediatric patients.
Lifestyle Recommendations
Based on expert recommendations, children should avoid
physical activity after acute attacks until the resolution of
symptoms and acute-phase reactants. Moreover, resumption
of competitive sports should occur not before 3 months
after complete remission of pericarditis. In case of frequent
recurrences avoidance of physical activity in children in our
opinion is less stringent, since it is important to allow a normal
or near-normal life in these children; the focus should be on a
therapy able to control the disease more than on restriction of
physical activity.
Exacerbations of SLE or autoinflammatory diseases are
sometimes associate with specific triggers, including sunlight
for SLE, and exercise, local injury, infection, cold exposure,
emotional stress, surgery and hormonal changes for FMF and
TRAPS. Patients with RP associated with these condition should
be advised to avoid potential triggers, especially if they have been
involved in previous disease flares.
The recommended vaccination schedule (120) may not
require changes for most children with RP. Prevention of
recurrences by influenza vaccination is not demonstrated,
reflecting that influenza is a rare trigger of RP. Subjects treated
with immunosuppressive agents might benefit from all available
inactivated vaccines, although immunogenicity might be reduced
and additional administrations be required. On the contrary, a
careful balance of the degree of immunocompromised, the risk
of natural exposure and the availability of non-live alternatives,
may be required for attenuated vaccines.
CONCLUSIONS
RP in children and adolescences has significant morbidity.
Multiple potential causes exist, although most of them
are related to either autoimmune or autoinflammatory
mechanisms. Recent advances allow to manage RP effectively
in almost all patients. However, a careful diagnostic work-
up and a correct therapeutic algorithm are required
to maximize efficacy while limiting avoidable costs and
side effects.
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